Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-2953 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypercalcemia and Acute Kidney Injury Associated with Disseminated Paracoccidioidomycosis.
Am J Trop Med Hyg
January 2025
Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Paracoccidioidomycosis is an acute to chronic systemic mycosis caused by the fungi Paracoccidioides. Hypercalcemia is a rare and not fully understood presentation of this infection. We present a case report of paracoccidioidomycosis associated with hypercalcemia and acute kidney injury (AKI) in an immunocompetent patient.
View Article and Find Full Text PDFMultiple Pyoderma Gangrenosum Overlying AV Fistula Treated With Colchicine: A Case Report.
Can J Kidney Health Dis
October 2024
Département de Médecine, Hôpital du Sacré-Coeur de Montréal, QC, Canada.
Article Synopsis
- - Pyoderma gangrenosum (PG) is a rare condition that causes painful ulcers, which can occur after trauma like needle insertion, a phenomenon known as pathergy; this report highlights a 69-year-old woman who developed PG after hemodialysis.
- - The patient experienced painful ulcers at the site of needle insertion on her arteriovenous fistula (AVF), prompting a diagnosis of PG following a thorough evaluation that ruled out other causes.
- - Treatment involved suspending dialysis through the AVF and using medications such as prednisone, topical corticosteroids, and colchicine to manage PG; her condition improved, allowing for safe resumption of dialysis while minimizing the risk of further complications.
Article Synopsis
- Pyoderma gangrenosum is a rare skin disease that causes painful ulcers with specific characteristics and can occur alongside other conditions like rheumatoid arthritis and inflammatory bowel disease.
- A unique case was reported involving a 67-year-old obese female who had both pyoderma gangrenosum and IgA vasculitis, leading to large, rapidly expanding skin wounds.
- Treatment with a TNF-α inhibitor (adalimumab) successfully reduced the ulceration and promoted healing after initial treatment with oral prednisolone.
Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group.
J Invest Dermatol
June 2024
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address:
At present, there are no standardized guidelines for determining patient eligibility for pyoderma gangrenosum (PG) clinical trials. Thus, we aim to determine which clinical features, histopathological features, or laboratory features should be included in active ulcerative PG clinical trial eligibility criteria for treatment-naïve patients and patients already treated with immunomodulating medications (treatment-exposed patients). This study employed 4 rounds of the Delphi technique.
View Article and Find Full Text PDFEcthyma gangrenosum in pediatric patients: 10-year experience at the National Institute of Pediatrics.
Int J Dermatol
November 2023
Dermatology Department, Instituto Nacional de Pediatría, Mexico City, Mexico.
Article Synopsis
- - Ecthyma gangrenosum (EG) is a skin condition mainly caused by Pseudomonas aeruginosa infections in immunocompromised patients, presenting with reddish-purple spots that can progress quickly to severe skin ulcers.
- - A study analyzed 17 EG patients, revealing that many had underlying conditions like acute lymphoblastic leukemia; most presented with systemic symptoms like fever and pain, and P. aeruginosa was the most commonly isolated bacteria.
- - The findings suggest that if a patient shows fever and pain with rapidly worsening skin lesions, physicians should suspect EG and start treatment without waiting for lab results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!